111
Participants
Start Date
August 23, 2018
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
Memantine
Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
Placebo
The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
Vanderbilt University Medical Center, Nashville
The Cleveland Clinic, Cleveland
The University of Texas Health Science Center, Houston, Houston
Collaborators (1)
Evergreen Therapeutics, Inc.
INDUSTRY
The University of Texas Health Science Center, Houston
OTHER
The Cleveland Clinic
OTHER
Vanderbilt University Medical Center
OTHER